Psoriasis. Diagnostic and therapeutic recommendations of the Polish Dermatological Society. Part I: Mild psoriasis

Abstract

Psoriasis is a chronic inflammatory skin disease affecting approximately 1-3% of the general population. Recent years have brought a considerable progress in the treatment of this dermatosis, particularly with respect to patients with moderate to severe psoriasis. A growing range of increasingly available systemic therapies poses new challenges to physicians providing care to patients with psoriasis. On account of the fact that new antipsoriatic drugs have become available on the pharmaceutical market since the publication of previous guidelines for the treatment of psoriasis, an update has become necessary. The first part of the guidelines refers to mild psoriasis and selected special forms of this disease. The aim of the recommendations of the Polish Dermatological Society is to summarize the most recent literature reports and formulate guidelines that may be potentially useful for dermatologists-venereologists in their daily clinical practice. However, the final decision regarding the diagnostic and therapeutic procedure should always be made individually for each patient based on the patient's current clinical status and the most up-to-date literature reports.

Signaling pathways associated with interleukins 12 and 23 and epigenetic mechanism of sequential-specific regulation of expression of related genes by miRNAs as molecular markers for assessing the potential of anti-cytokine therapies

“…Mianem leków biologicznych określa się grupę substancji biologicznie czynnych, takich jak peptydy, białka, które zostały przygotowane dzięki technikom biologii molekularnej i inżynierii genetycznej. Aktualnie dostępnych jest kilka grup leków biologicznychrekombinowane białka ludzkie, białka fuzyjne, przeciwciała monoklonalne [4,5].…”

“…Given the above, seeking new molecular markers that would allow for determining treatment efficacy and notice the lack of adequate response to the applied therapeutic strategy at an early stage, regardless of the therapy or drug type, is of the essence [4,5,13].…”

“…Z tego względu niezwykle istotne jest poszukiwanie nowych molekularnych markerów, które niezależnie od rodzaju terapii i wyboru leku pozwoliłyby określić efektywność leczenia oraz na wczesnym etapie wychwycić brak adekwatnej odpowiedzi na stosowaną strategię terapeutyczną [4,5,13].…”

“…Contraindications to commence a biological therapy include: hypersensitivity to a given drug or its components, pregnancy, and lactation. Moreover, immunosuppressive aspect of the treatment should also be taken into account as it translates into a possible occurrence of more frequent exacerbation of concurrent diseases such as liver and bile duct diseases, hepatitis, circulatory insufficiency, HIV infections, collagenoses, or occurrence of infections caused by: Nocardia sp., Pneumocystis carinii, Coccidioides immitis, Histoplasma capsulatum, Aspergillus sp., Listeria monocytogenes [4,5].…”

“…Biological drugs constitute a group of biologically active substances such as: peptides and proteins that have been prepared by applying molecular biology and genetic engineering techniques. Currently, several groups of biological drugs are available: recombinant human proteins, fusion proteins, and monoclonal antibodies [4,5].…”